Feb 28, 2023 04:00PM

Nov 9, 2022 04:01PM

Oct 3, 2022 08:30AM

May 12, 2022 04:01PM

May 12, 2022 04:01PM

Mar 30, 2022 08:00AM

Mar 30, 2022 08:00AM Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Mar 9, 2022 04:03PM

Mar 9, 2022 04:01PM

Mar 9, 2022 04:01PM

Jan 12, 2022 08:30AM

Jan 12, 2022 08:30AM

Dec 7, 2021 07:00AM

Dec 7, 2021 07:00AM Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Dec 29, 2017 07:03AM

Dec 29, 2017 07:00AM

Dec 22, 2017 09:20AM

Dec 22, 2017 06:10AM

Dec 22, 2017 01:00AM

Nov 7, 2017 04:00PM

Oct 18, 2017 06:10AM Ignyta (RXDX) Says Interim Analysis of its Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive NSCLC

Oct 17, 2017 10:55PM

Oct 17, 2017 07:08AM

Oct 17, 2017 07:00AM

Sep 11, 2017 08:02AM

Sep 11, 2017 08:00AM

Sep 6, 2017 09:25AM

Sep 6, 2017 08:03AM Ignyta (RXDX) Offers Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program

Sep 6, 2017 08:00AM

Aug 8, 2017 04:00PM

Jul 10, 2017 07:04AM

Jul 10, 2017 07:00AM

May 15, 2017 09:31AM

May 15, 2017 07:15AM

May 15, 2017 07:00AM Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration

Apr 27, 2017 05:00PM

Mar 14, 2017 04:00PM

322,086 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All